title: Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097).
abstract: BACKGROUND
  Both highly potent antiretroviral drug rescue therapy and treatment interruption have been suggested to be effective in patients with multiple treatment failure.
  
  
  OBJECTIVE
  To assess both the benefits and risks of an 8-week treatment interruption associated with a six to nine-drug rescue regimen in patients with multiple treatment failures.
  
  
  METHODS
  A randomized comparative controlled trial in 19 university hospitals in France.
  
  
  METHODS
  Sixty-eight HIV-infected patients with multiple previous treatment failures and CD4 cell counts less than 200 x 10(6) cells/l and plasma HIV-1-RNA levels of 50,000 copies/ml or greater.
  
  
  METHODS
  The primary efficacy outcome was the proportion of patients with at least a 1 log10 decrease (copies/ml) in the plasma HIV-1-RNA level after 12 weeks of therapy.
  
  
  RESULTS
  Treatment interruption followed by multidrug salvage therapy led to a greater proportion of patients achieving virological success (i.e. 1 log10 decrease) at 12 weeks compared with patients receiving multidrug therapy alone (62 versus 26%, intent-to-treat analysis; P = 0.007). The median decrease in the HIV-1-RNA level was -1.91 and -0.37 log10 copies/ml (P = 0.008), respectively. Treatment interruption led to an increase in the number of sensitive drugs of the multidrug regimen (71 versus 35% of regimen with at least two sensitive drugs; P = 0.004). Factors associated with virological success were treatment interruption, the reversion of at least one mutation to wild type, adequate plasma drug concentration, and the use of lopinavir.
  
  
  CONCLUSIONS
  Treatment interruption was beneficial for treatment-experienced HIV-infected patients with advanced HIV disease and multidrug-resistant virus.
authors.affiliation: Département des Maladies Infectieuses et Tropicales/INSERM E 0214, Hôpital Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France. christine.katlama@psl.ap-hop-paris.fr
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Dominguez
authors.forename: Karine
authors.initials: K
authors.lastname: Gourlain
authors.forename: Claudine
authors.initials: C
authors.lastname: Duvivier
authors.forename: Constance
authors.initials: C
authors.lastname: Delaugerre
authors.forename: Mayeule
authors.initials: M
authors.lastname: Legrand
authors.forename: Roland
authors.initials: R
authors.lastname: Tubiana
authors.forename: Jacques
authors.initials: J
authors.lastname: Reynes
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Molina
authors.forename: Gilles
authors.initials: G
authors.lastname: Peytavin
authors.forename: Vincent
authors.initials: V
authors.lastname: Calvez
authors.forename: Dominique
authors.initials: D
authors.lastname: Costagliola
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D044966:Anti-Retroviral Agents / Q000097:blood; D023241:Antiretroviral Therapy, Highly Active; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016879:Salvage Therapy; D017211:Treatment Failure
chemical_list: D044966:Anti-Retroviral Agents